RapifleX MALDI PharmaPulse
rapifleX MALDI PharmaPulse
The rapifleX® MALDI PharmaPulse® accelerates the drug discovery process utilizing label-free mass spectrometry for uHTS.
High-Throughput Screening
Unique speed and specificity offered by label-free MALDI-TOF mass spectrometry
The all new rapifleX® MALDI Time-of-Flight mass spectrometer is the heart of the MALDI PharmaPulse®, it incorporates Brukers latest 10 kHz scanning laser technology and can read multiple samples per second. All components of the system work in concert for fully automatic HTS operation. The newly designed screening software suite supports HTS workflows and works in combination with a proprietary assay development module which empowers assay developer to accelerate label-free assay development for MALDI mass spectrometry. The latest ‚Synthesis Screening‘ software module of the rapifleX® MPP opens a new application space for e.g. monitoring of chemical reactions at high pace or analysis of binding assays at incomparable high throughput and specificity.
rapifleX® MALDI PharmaPulse® (MPP) combs through large compound libraries of millions of substances
The use of mass spectrometry allows the measurement of unmodified substrates in primary screens to avoid false positives or false negatives, making confirmation screens redundant. The system is designed for fully automatic handling of 384 and 1536 sample plates to screen more than a million compounds in a week in support of drug discovery.
New standard for ultra-High-Throughput Screening Label-Free ‘Hit’ Identification
By combining the speed of Bruker’s patented smartbeam 3D laser technology with the direct-detection capability of mass spectrometry, the rapifleX® MPP delivers unprecedented screening capability for ultra high-throughput screening of biochemical and cellular assays. It allows you to screen through large and diverse compound libraries at a pace of over a million compounds a week, epitomizing the perfect balance of automation and miniaturization.
The MPP system allows for the measurement of unmodified substrates in primary biochemical screens, and offers several advantages:
- It effectively eliminates confirmatory assays typically required of traditional fluorescence-based screening techniques
- Saves costs for developing specific fluorescence probes or antibodies
- Doesn’t require expensive solvents or consumables for continuous operation
- Allows sample volume down to 25 nL
PharmaPulse Solution
The PharmaPulse Solution is based on Bruker´s advanced MALDI-TOF technology and on a dedicated software package. Ease of use and time to result were key drivers during the development resulting in an intuitive but yet powerful software solution to measure and analyze millions of samples in full automation. Two workflows guide the user from adapting an assay to MALDI mass spectrometry to readily exported results for further analysis in LIMS systems.
